Abstract
Treatment options are limited for non-muscle-invasive bladder cancer patients having failed BCG treatment who cannot undergo cystectomy. While results from ongoing clinical trials are awaited, data have emerged suggesting that combination of agents having previously demonstrated safety and efficacy in this setting can help a large percentage of our patients. These data should not be ignored.
Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.
MeSH terms
-
Adjuvants, Immunologic / administration & dosage
-
Adjuvants, Immunologic / adverse effects
-
Antineoplastic Agents / therapeutic use
-
BCG Vaccine* / administration & dosage
-
BCG Vaccine* / adverse effects
-
Carcinoma, Transitional Cell* / drug therapy
-
Carcinoma, Transitional Cell* / pathology
-
Carcinoma, Transitional Cell* / surgery
-
Clinical Trials as Topic
-
Cystectomy / methods*
-
Doxorubicin / analogs & derivatives*
-
Doxorubicin / therapeutic use
-
Humans
-
Neoplasm Grading
-
Neoplasm Recurrence, Local* / pathology
-
Neoplasm Recurrence, Local* / therapy
-
Neoplasm Staging
-
Patient Selection
-
Practice Guidelines as Topic
-
Urinary Bladder Neoplasms* / drug therapy
-
Urinary Bladder Neoplasms* / pathology
-
Urinary Bladder Neoplasms* / surgery
Substances
-
Adjuvants, Immunologic
-
Antineoplastic Agents
-
BCG Vaccine
-
valrubicin
-
Doxorubicin